CYP2W1 polymorphism: Functional aspects and relation to risk for colorectal cancer

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1615-1622

  Stenstedt, Kristina ^a,b   Travica, Sandra ^b   Guo, Jia ^b   Barragan, Isabel ^b   Pors, Klaus ^c   Patterson, Laurence ^c   Edler, David ^a   Mkrtchian, Souren ^b   Johansson, Inger ^b   Ingelman Sundberg, Magnus ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

anticancer therapy; colon cancer; cytotoxicity; drug metabolism; epidemiology; indolines

Indexed keywords

CYP2W1 PROTEIN; CYTOCHROME; DUOCARMYCIN DERIVATIVE; ICT 2706; ICT 2726; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; CYP2W1 GENE; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PROTEIN EXPRESSION; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 84885415836     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.136     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 375(9719), 1030-1047 (2010).
3. Broderick P, Carvajal-Carmona L, Pittman AM et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet. 39(11), 1315-1317 (2007).
4. Houlston RS, Webb E, Broderick P et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet. 40(12), 1426-1435 (2008).
5. Tomlinson IP, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10 p14 and 8 q23.3. Nat. Genet. 40(5), 623-630 (2008).
6. Karlgren M, Gomez A, Stark K et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341(2), 451-458 (2006). Demonstrates the cloning of CYP2W1 and its presence in rat fetal colon and specifically in human colon tumors.
7. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M. Expression of CYP2W1 in colon tumors: Regulation by gene methylation. Pharmacogenomics 8(10), 1315-1325 (2007).
8. Edler D, Stenstedt K, Ohrling K et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-A pilot study. Eur. J. Cancer 45(4), 705-712 (2009). Demonstrates that expression of CYP2W1 is indicative of the malignancy of colorectal tumors.
9. Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: A prognostic marker in colon cancer. Anticancer Res. 32(9), 3869-3874 (2012).
10. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum. Genet. 127(1), 1-17 (2010).
11. Hanzawa Y, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Genetic polymorphisms and haplotype structures of the human CYP2W1 gene in a Japanese population. Drug Metab. Dispos. 36(2), 349-352 (2008).
12. Wu ZL, Sohl CD, Shimada T, Guengerich FP. Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol. Pharmacol. 69(6), 2007-2014 (2006).
13. Gomez A, Nekvindova J, Travica S et al. Colorectal cancer-specific cytochrome P450 2W1: Intracellular localization, glycosylation, and catalytic activity. Mol. Pharmacol. 78(6), 1004-1011 (2010).
14. Nishida CR, Lee M, De Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol. Pharmacol. 78(3), 497-502 (2010).
15. Xiao Y, Guengerich FP. Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J. Lipid Res. 53(8), 1610-1617 (2012).
16. Travica S, Pors K, Loadman PM et al. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin. Cancer Res. 19(11), 2952-2961 (2013). Demonstrates that CYP2W1 can metabolize duocarmycin analogs to cytotoxic products at low concentrations, which causes abolished growth of colon tumors in mice xenograft models.
17. Gervasini G, De Murillo SG, Ladero JM, Agundez JA. CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A Ala181Thr) polymorphism with increased colorectal cancer risk. Pharmacogenomics 11(7) 919-925 ( 2010). Suggests a relationship between polymorphic variants of the CYP2W1 gene and risk for colorectal cancer.
18. Mkrtchian S, Fang C, Hellman U, Ingelman-Sundberg M. A stress-inducible rat liver endoplasmic reticulum protein, ERp29. Eur. J. Biochem. 251(1-2), 304-313 (1998).
19. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25(11), 1679-1691 (2006).